Jasper Therapeutics, Inc. (JSPR)
NASDAQ: JSPR · Real-Time Price · USD
1.480
-0.070 (-4.52%)
At close: Jan 30, 2026, 4:00 PM EST
1.510
+0.030 (2.03%)
After-hours: Jan 30, 2026, 6:32 PM EST

Jasper Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-91.02-71.27-64.47-37.69-30.64-31.67
Depreciation & Amortization
1.011.371.110.980.38-
Loss (Gain) From Sale of Assets
0.010.01----
Stock-Based Compensation
7.026.625.214.091.051.21
Other Operating Activities
0.910.490.98-12.59-6.0910.9
Change in Accounts Receivable
--0.66-0.660.6-
Change in Accounts Payable
6.1-0.122.38-2.152.940.36
Change in Other Net Operating Assets
-0.460.32.062.17-1.920.94
Operating Cash Flow
-76.43-62.6-52.07-45.86-33.68-18.27
Capital Expenditures
-0.1-0.55-0.27-0.58-2.43-
Sale of Property, Plant & Equipment
0.030.02----
Investing Cash Flow
-0.07-0.53-0.27-0.58-2.43-
Issuance of Common Stock
34.947.88101.930.060.240.05
Repurchase of Common Stock
---0.96---
Other Financing Activities
----89.98-
Financing Cash Flow
34.947.88100.970.06100.9711.29
Net Cash Flow
-41.6-15.2548.64-46.3864.86-6.98
Free Cash Flow
-76.53-63.15-52.33-46.43-36.11-18.27
Free Cash Flow Per Share
-4.87-4.33-5.01-12.73-31.69-105.60
Levered Free Cash Flow
-42.69-39.59-30.35-29.17-22.8-10.54
Unlevered Free Cash Flow
-42.69-39.59-30.35-29.17-22.8-10.54
Change in Working Capital
5.640.175.1-0.651.621.3
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q